The first and second HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA, Vorinostat) and romidepsin, respectively, are approved for treating cutaneous T-cell lymphoma (CTCL). The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.